New

Anxiety Disorders And Depression Therapeutic Drug Market

2021

Anxiety Disorders And Depression Therapeutic Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), Buspirone, Others); Treatment Indication (OCD (Obsessive Compulsive Disorder), Phobias, Panic Disorders, Others); End User (Hospitals, Mental Healthcare Centers, Asylums, Others) and Geography

| Report Code: TIPRE00018817 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Anxiety Disorders And Depression Therapeutic Drug Market 2028 By Drug Class, Treatment Indication, End User and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Depression and anxiety disorders are one of the most common psychiatric disorders affecting a vast population worldwide. Depression; is related to a state of emotion that further affects actions, thoughts, and sometimes the sleeping pattern of the concerned person. Depression is the most common type of mental disorder affecting nearly 350 million patients of varied scale age groups, whereas anxiety is a stress reaction. An extreme level of pressure results in anxiety disorders, which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder. Anxiety disorders include obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder (PTSD), and phobias. Anxiety disorders are the most prevalent psychiatric disorders and are associated with a high burden of illness.

MARKET DYNAMICS

The anxiety disorders and depression therapeutic drug market has shown a significant evolution over the forecast period. The rise of anxiety disorders and depression is driven by the rising geriatric population which majorly drives the therapeutic drug market, reduced side effects, and greater efficacy of new/innovative drugs along with the accelerating prevalence of anxiety & depression disorders. As per data by the World Health Organization in 2012, depressive disorder affected 350 million people globally, which is expected to increase due to the upward trend in adopting sedentary lifestyles. Depression is the second-leading cause of disabilities globally, raising the need to develop innovative medications shortly. Furthermore, the presence of favorable reimbursement policies in developed countries for medications and therapies coupled with their high success rates are anticipated to drive the growth over the forecast period. However, patent expiration of most drugs combined with the increasing rate of drug withdrawals and the introduction of generic variants on a large scale is expected to restrain the growth of the anxiety disorders and depression therapeutic drug market.

MARKET SCOPE

The "Anxiety Disorders and Depression Therapeutic Drug Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry's pharmaceuticals, focusing on the global market trend analysis. This report outlines the anxiety disorders and depression therapeutic drug market with detailed market segmentation by drug class, treatment indication, and end-user. The anxiety disorders and depression therapeutic drug market is estimated to witness a high rise during the forecast period. It focuses on the vital statistics on the leading players' market status in the anxiety disorders and depression therapeutic drug market and provides key opportunities and trends in the market.

MARKET SEGMENTATION

The market is categorized based on the drug class, treatment indication, and end user. Based on the drug class, the market is segmented as SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors),TCAs (Tricyclic Antidepressants), buspirone, and others. Based on the treatment indication, the segmentation of the market is into OCD (Obsessive Compulsive Disorder), phobias, panic disorders, others. Based on end user, the segmentation of the market is into hospitals, mental healthcare centers, asylums, and others.

REGIONAL FRAMEWORK

The report states a detailed outline of the industry, consisting of both quantitative and qualitative information. It offers a sketch and forecast of the anxiety disorders and depression therapeutic drug market based on various segments. The report also consists of market size and forecast estimates from the year 2020 to2028with respect to five main regions, namely; North America, Asia-Pacific (APAC), Europe, Middle East, and Africa (MEA), and South & Central America (SCAM). The anxiety disorders and depression therapeutic drug market by each region is then sub-segmented into respective countries and segments. It comprises the analysis and forecast of 18 countries globally and the recent trend and opportunities prevailing in the region.

The report analyzes factors affecting the anxiety disorders and depression therapeutic drug market from both the demand and supply sides. Furthermore, it evaluates market dynamics regarding the market during the forecast period, i.e., drivers, restraints, opportunities, and future trends. It also consists of precise PEST analysis for all five regions, namely, North America, Asia Pacific, Europe, Middle East, and Africa, and South & Central America, after assessing political, social, economic, and technological factors affecting the Anxiety disorders and depression therapeutic drug market in these regions.



Get more information on this report :

MARKET PLAYERS


The report contains critical developments in the anxiety disorders and depression therapeutic drug market as inorganic and organic growth strategies. Several companies are pivoting on organic growth strategies like product launches, product approvals, and others, such as patents and events. Inorganic growth strategies observed were collaborations and acquisitions &partnerships. Various such activities have paved the path for elaborating the business and customer base of market players. The market players from the anxiety disorders and depression therapeutic drug market are estimated to have profitable growth opportunities in the coming years with the higher demand for anxiety disorders and depression therapeutic drugs in the global market. Given below is the list of a few companies engaged in the anxiety disorders and depression therapeutic drug market.
The report also offers key players' profiles in the anxiety disorders and depression therapeutic drug market, along with their SWOT analysis and market strategies. Also, the report focuses on the key market players with information on company profiles, financial information of the last three years, components, and services provided, critical development in the past five years.
- GlaxoSmithKline plc.
- Eli Lilly and Company.
- Forest Laboratories, Inc.
- AstraZeneca
- sanofi-aventis U.S. LLC
- Merck & Co., Inc.
- Pfizer, Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- H. Lundbeck A/S
The Insight Partner's dedicated research and the analytical team comprises of experienced professionals with advanced statistical expertise and offers several customization options in the current report.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Anxiety Disorders And Depression Therapeutic Drug Market - By Drug Class
1.3.2 Anxiety Disorders And Depression Therapeutic Drug Market - By Treatment Indication
1.3.3 Anxiety Disorders And Depression Therapeutic Drug Market - By End User
1.3.4 Anxiety Disorders And Depression Therapeutic Drug Market - By Region
1.3.4.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG - GLOBAL MARKET OVERVIEW
6.2. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE

7. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. SSRIS (SELECTIVE SEROTONIN REUPTAKE INHIBITORS)
7.3.1. Overview
7.3.2. SSRIs (Selective Serotonin Reuptake Inhibitors) Market Forecast and Analysis
7.4. SNRIS (SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS)
7.4.1. Overview
7.4.2. SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast and Analysis
7.5. TCAS (TRICYCLIC ANTIDEPRESSANTS)
7.5.1. Overview
7.5.2. TCAs (Tricyclic Antidepressants) Market Forecast and Analysis
7.6. BUSPIRONE
7.6.1. Overview
7.6.2. Buspirone Market Forecast and Analysis
7.7. OTHERS
7.7.1. Overview
7.7.2. Others Market Forecast and Analysis
8. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT INDICATION
8.1. OVERVIEW
8.2. TREATMENT INDICATION MARKET FORECASTS AND ANALYSIS
8.3. OCD (OBSESSIVE COMPULSIVE DISORDER)
8.3.1. Overview
8.3.2. OCD (Obsessive Compulsive Disorder) Market Forecast and Analysis
8.4. PHOBIAS
8.4.1. Overview
8.4.2. Phobias Market Forecast and Analysis
8.5. PANIC DISORDERS
8.5.1. Overview
8.5.2. Panic Disorders Market Forecast and Analysis
8.6. OTHERS
8.6.1. Overview
8.6.2. Others Market Forecast and Analysis
9. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET - REVENUE AND FORECASTS TO 2028 - END USER
9.1. OVERVIEW
9.2. END USER MARKET FORECASTS AND ANALYSIS
9.3. HOSPITALS
9.3.1. Overview
9.3.2. Hospitals Market Forecast and Analysis
9.4. MENTAL HEALTHCARE CENTERS
9.4.1. Overview
9.4.2. Mental Healthcare Centers Market Forecast and Analysis
9.5. ASYLUMS
9.5.1. Overview
9.5.2. Asylums Market Forecast and Analysis
9.6. OTHERS
9.6.1. Overview
9.6.2. Others Market Forecast and Analysis

10. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Anxiety Disorders And Depression Therapeutic Drug Market Overview
10.1.2 North America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis
10.1.3 North America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Drug Class
10.1.4 North America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Treatment Indication
10.1.5 North America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By End User
10.1.6 North America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Countries
10.1.6.1 United States Anxiety Disorders And Depression Therapeutic Drug Market
10.1.6.1.1 United States Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.1.6.1.2 United States Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.1.6.1.3 United States Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.1.6.2 Canada Anxiety Disorders And Depression Therapeutic Drug Market
10.1.6.2.1 Canada Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.1.6.2.2 Canada Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.1.6.2.3 Canada Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.1.6.3 Mexico Anxiety Disorders And Depression Therapeutic Drug Market
10.1.6.3.1 Mexico Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.1.6.3.2 Mexico Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.1.6.3.3 Mexico Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2. EUROPE
10.2.1 Europe Anxiety Disorders And Depression Therapeutic Drug Market Overview
10.2.2 Europe Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis
10.2.3 Europe Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Drug Class
10.2.4 Europe Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Treatment Indication
10.2.5 Europe Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By End User
10.2.6 Europe Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.1.1 Germany Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.1.2 Germany Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.1.3 Germany Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2.6.2 France Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.2.1 France Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.2.2 France Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.2.3 France Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2.6.3 Italy Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.3.1 Italy Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.3.2 Italy Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.3.3 Italy Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2.6.4 Spain Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.4.1 Spain Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.4.2 Spain Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.4.3 Spain Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2.6.5 United Kingdom Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.5.1 United Kingdom Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.5.2 United Kingdom Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.5.3 United Kingdom Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.2.6.6 Rest of Europe Anxiety Disorders And Depression Therapeutic Drug Market
10.2.6.6.1 Rest of Europe Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.2.6.6.2 Rest of Europe Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.2.6.6.3 Rest of Europe Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Overview
10.3.2 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis
10.3.3 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Drug Class
10.3.4 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Treatment Indication
10.3.5 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By End User
10.3.6 Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.1.1 Australia Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.1.2 Australia Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.1.3 Australia Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3.6.2 China Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.2.1 China Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.2.2 China Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.2.3 China Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3.6.3 India Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.3.1 India Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.3.2 India Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.3.3 India Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3.6.4 Japan Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.4.1 Japan Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.4.2 Japan Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.4.3 Japan Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3.6.5 South Korea Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.5.1 South Korea Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.5.2 South Korea Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.5.3 South Korea Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.3.6.6 Rest of Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market
10.3.6.6.1 Rest of Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.3.6.6.2 Rest of Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.3.6.6.3 Rest of Asia-Pacific Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Overview
10.4.2 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis
10.4.3 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Drug Class
10.4.4 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Treatment Indication
10.4.5 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By End User
10.4.6 Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Anxiety Disorders And Depression Therapeutic Drug Market
10.4.6.1.1 South Africa Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.4.6.1.2 South Africa Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.4.6.1.3 South Africa Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.4.6.2 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Market
10.4.6.2.1 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.4.6.2.2 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.4.6.2.3 Saudi Arabia Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.4.6.3 U.A.E Anxiety Disorders And Depression Therapeutic Drug Market
10.4.6.3.1 U.A.E Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.4.6.3.2 U.A.E Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.4.6.3.3 U.A.E Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.4.6.4 Rest of Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market
10.4.6.4.1 Rest of Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.4.6.4.2 Rest of Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.4.6.4.3 Rest of Middle East and Africa Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Overview
10.5.2 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis
10.5.3 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Drug Class
10.5.4 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Treatment Indication
10.5.5 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By End User
10.5.6 South and Central America Anxiety Disorders And Depression Therapeutic Drug Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Anxiety Disorders And Depression Therapeutic Drug Market
10.5.6.1.1 Brazil Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.5.6.1.2 Brazil Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.5.6.1.3 Brazil Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.5.6.2 Argentina Anxiety Disorders And Depression Therapeutic Drug Market
10.5.6.2.1 Argentina Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.5.6.2.2 Argentina Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.5.6.2.3 Argentina Anxiety Disorders And Depression Therapeutic Drug Market by End User
10.5.6.3 Rest of South and Central America Anxiety Disorders And Depression Therapeutic Drug Market
10.5.6.3.1 Rest of South and Central America Anxiety Disorders And Depression Therapeutic Drug Market by Drug Class
10.5.6.3.2 Rest of South and Central America Anxiety Disorders And Depression Therapeutic Drug Market by Treatment Indication
10.5.6.3.3 Rest of South and Central America Anxiety Disorders And Depression Therapeutic Drug Market by End User

11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

12. ANXIETY DISORDERS AND DEPRESSION THERAPEUTIC DRUG MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC.
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. ELI LILLY AND COMPANY.
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. FOREST LABORATORIES, INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ASTRAZENECA
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. SANOFI-AVENTIS U.S. LLC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. MERCK & CO., INC.
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. PFIZER, INC.
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. JOHNSON & JOHNSON SERVICES, INC.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. BRISTOL-MYERS SQUIBB COMPANY
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. H. LUNDBECK A/S
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments

13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. GlaxoSmithKline plc.
2. Eli Lilly and Company.
3. Forest Laboratories, Inc.
4. AstraZeneca
5. sanofi-aventis U.S. LLC
6. Merck & Co., Inc.
7. Pfizer, Inc.
8. Johnson & Johnson Services, Inc.
9. Bristol-Myers Squibb Company
10. H. Lundbeck A/S
TIPRE00018817
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.